-
1 Comment
Respiri Limited is currently in a long term downtrend where the price is trading 46.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Respiri Limited's total revenue sank by 43.8% to $1M since the same quarter in the previous year.
Its net income has dropped by 349.3% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 100.5% to $-2M since the same quarter in the previous year.
Based on the above factors, Respiri Limited gets an overall score of 1/5.
| Exchange | AU |
|---|---|
| CurrencyCode | AUD |
| ISIN | AU000000RSH4 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Beta | -0.44 |
|---|---|
| Market Cap | 52M |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia and the United States. The company develops, produces, and sells mobile health applications. Its products include wheezo, a wheeze rate detector; respiri mobile application; and Respiri health portal. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. The company was incorporated in 1987 and is based in Melbourne, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RSH.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
